No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
www.purapharm.comNo one on the platform currently holds 1498.HK.
No tracked institution reports a position in 1498.HK as of their last filing.
No one on the platform has traded 1498.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -12.0% | -11.0% | ||||
| Profit Margin % | -10.5% | -18.2% | -10.9% | |||
| Free Cash Flow Margin % | 7.6% | 9.5% | 1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $694M | — | $0.08 | $0.08–$0.08 | — | 1 |
| 2028 | $761M | +9.6% | $0.03 | $0.03–$0.03 | — | 1 |
| 2029 | $645M | -15.2% | $0.03 | $0.03–$0.03 | — | 1 |
| 2030 | $743M | +15.1% | $0.06 | $0.06–$0.06 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $0.08 |
| -1.23% |
| $232M |
| — |
| 0911.HKQianhai Health Holdings Limited | $0.38 | -5.00% | $64M | — |
| 0928.HKKing International Investment Limited | $0.14 | -2.11% | $257M | — |
Source: Financial Modeling Prep · peers by sector/industry